OROS metilfenidattan modifiye- salınımlı metilfenidata geçişte psikotik belirtiler

Dikkat eksikliği hiperaktivite bozukluğunun (DEHB) ilk sıra ilaç tedavisi olan metilfenidat (MPH) ile davranışsal yan etkiler ortaya çıkabilmektedir. Bu yan etkiler arasında, psikotik belirtiler klinisyenler için en zorlayıcı olanlar arasındadır. Suboptimal belirti kontrolü olan DEHB olgularında MPH preparatları arasında geçişler faydalı olabilmektedir. Uzun etkili MPH preparatlarının yan etki riskleri açısından muhtemel farklılıkları yeterli düzeyde bilinmemektedir. Bu yazıda, OROS metilfenidattan modifiye-salınımlı metilfenidata geçişte psikotik belirtiler ortaya çıkan bir çocuk olgu sunulmuştur.

Psychotic symptoms associated with switching from OROS methylphenidate to modified-release methylphenidate

Methylphenidate (MPH), the firstline medication treatment of attention deficit hyperactivity disorder (ADHD), may be associated with behavioral adverse effects. Amongst these reactions, psychotic symptoms are the most challenging ones for clinicans. For ADHD patients with suboptimal symptom control, switching MPH formulations may be helpful. The possible differences in the risk of adverse effects between long acting MPH formulations is largely unknown. Hereby, we report a child case who developed psychotic symptoms when switching from osmotic release oral system (OROS) MPH to modified-release MPH.

PDF

___

1. Pliszka S, AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2007; 46:894-921.
2. Ross RG. Psychotic and manic-like symptoms during stimulant treatment of Attention Deficit Hyperactivity Disorder. Am J Psychiatry 2006; 163:1149-1152.
3. Shibib S, Chalhoub N. Stimulant induced psychosis. Child Adolesc Ment Health 2009; 14:20-23.
4. Czerniak SM, Sikoglu EM, King JA, Kennedy DN, Mick E, Frazier J, et al. Areas of the brain modulated by single-dose methylphenidate treatment in youth with ADHD during task-based fMRI: A systematic review. Harv Rev Psychiatry 2013; 21:151-162.
5. Döpfner M, Ose C, Fischer R, Ammer R, Scherag A. Comparison of the efficacy of two different modified release methylphenidate preparations for children and adolescents with attention-deficit/ hyperactivity disorder in a natural setting: comparison of the efficacy of Medikinet(®) retard and Concerta(®)--a randomized, controlled, doubleblind multicenter clinical crossover trial. J Child Adolesc Psychopharmacol 2011; 21:445-454.
6. Coghill D, Banaschewski T, Zuddas A, Pelaz A, Gagliano A, Doepfner M. Long-acting methylphenidate formulations in the treatment of attention-deficit/hyperactivity disorder: a systematic review of head-to-head studies. BMC Psychiatry 2013; 27(13):237.
7. Modi NB, Lindemulder B, Gupta SK. Single- and multiple-dose pharmacokinetics of an oral once-aday osmotic controlled-release OROS (methylphenidate HCl) formulation. J Clin Pharmacol 2000; 40:379-388.
8. Pierce D, Katic A, Buckwalter M, Webster K. Single- and multiple-dose pharmacokinetics of methylphenidate administered as methylphenidate transdermal system or osmotic-release oral system methylphenidate to children and adolescents with attention deficit hyperactivity disorder. J Clin Psychopharmacol 2010; 30:554-564.
9. Ekinci O, Sabuncuoglu O. Psychosis associated with switching from risperidone to aripiprazole in an adolescent on methylphenidate treatment. Prog Neuropsychopharmacol Biol Psychiatry 2011; 30:648-649.
10. Sabuncuoglu O. Risperidone-to-methylphenidate switch reaction in children: three cases. J Psychopharmacol 2007; 21:216-219.